Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)

AbstractAnti-CD19 Chimeric Antigen Receptor T cells (CAR-T) have shown dramatic efficacy in treating refractory aggressive B cell Lymphomas leading to FDA approval of axicabtagene ciloleucel and ti...